Latest News-SHANGHAI PHARMATECHS CO.LTD Mediaroom_Page

WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics

SHANGHAI, April 7, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufactu...

2022-04-08 08:00 1727

WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics

WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies

PHILADELPHIA, March 7, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subs...

2022-03-08 08:00 1343

WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories

SHANGHAI, Feb. 10, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced that...

2022-02-11 10:00 1607

WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories

Statement by WuXi AppTec Regarding Recent Market Fluctuation

SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confi...

2021-12-16 08:00 2295

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufactur...

2021-12-09 08:00 1863

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

PHILADELPHIA, Oct. 17, 2021 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owne...

2021-10-18 11:05 1514

WuXi AppTec Receives AA ESG Rating from MSCI

SHANGHAI, Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleased to announce that Mor...

2021-09-06 08:00 2258

WuXi AppTec Receives AA ESG Rating from MSCI

WuXi AppTec Reports Strong 2021 Interim Results

* Revenue Up 45.7% Year-Over-Year to RMB10,537 Million * Net Profit Attributable to Owners of th...

2021-08-12 17:52 2889

WuXi AppTec Reports Strong 2020 Annual Results

Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Compan...

2021-03-30 21:10 2739

WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award

SHANGHAI, Dec. 2, 2020 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufactur...

2020-12-03 08:00 1728

ViGeneron and WuXi Advanced Therapies Enter Strategic Manufacturing Partnership for Next-Generation Ophthalmic Gene Therapy

PHILADELPHIA and MUNICH, Dec. 1, 2020 /PRNewswire/ -- ViGeneron, a gene therapy company, and WuXi A...

2020-12-01 21:00 2532

WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-The-Art Testing Laboratory

PHILADELPHIA, Nov. 18, 2020 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a business un...

2020-11-18 21:00 1523

WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

WuXi AppTec Second-Quarter 2020 Results Revenue Up 29.4% YoY to RMB4,044 Million Net Profit Attribu...

2020-08-13 16:49 4911

WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia

SHANGHAI and SAN DIEGO, July 9, 2020 /PRNewswire/ -- WuXi AppTec is pleased to announce that they a...

2020-07-09 16:32 1448

Latest News